Immunocore Holdings PLC
NASDAQ:IMCR

Watchlist Manager
Immunocore Holdings PLC Logo
Immunocore Holdings PLC
NASDAQ:IMCR
Watchlist
Price: 32.28 USD 0.5% Market Closed
Market Cap: 1.6B USD
Have any thoughts about
Immunocore Holdings PLC?
Write Note

Immunocore Holdings PLC
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Immunocore Holdings PLC
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Immunocore Holdings PLC
NASDAQ:IMCR
Additional Paid In Capital
ÂŁ1.1B
CAGR 3-Years
N/A
CAGR 5-Years
39%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Additional Paid In Capital
$987.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Additional Paid In Capital
ÂŁ364.6m
CAGR 3-Years
44%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Additional Paid In Capital
$1B
CAGR 3-Years
20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Additional Paid In Capital
$1.5B
CAGR 3-Years
58%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Additional Paid In Capital
ÂŁ179.1m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
5%
No Stocks Found

Immunocore Holdings PLC
Glance View

Market Cap
1.6B USD
Industry
Biotechnology

Immunocore Holdings Plc operates as a holding company. The company is headquartered in Abingdon, Oxfordshire and currently employs 324 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of TCR bispecific immunotherapies called Immune mobilizing monoclonal TCRs Against X disease (ImmTAX) designed to treat diseases, including cancer, infectious and autoimmune. The firm is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s pipeline is leveraging ImmTAX platform within three therapeutic areas: oncology, infectious disease and autoimmune disease. Its product candidate KIMMTRAK is used for positive adult patients with unresectable or metastatic uveal melanoma (mUM) having demonstrated in Phase III clinical trial.

IMCR Intrinsic Value
118.25 USD
Undervaluation 73%
Intrinsic Value
Price

See Also

What is Immunocore Holdings PLC's Additional Paid In Capital?
Additional Paid In Capital
1.1B GBP

Based on the financial report for Dec 31, 2023, Immunocore Holdings PLC's Additional Paid In Capital amounts to 1.1B GBP.

What is Immunocore Holdings PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
39%

Over the last year, the Additional Paid In Capital growth was 829%.

Back to Top